Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris Inc. reports developments in synthetic biology, industrial biotechnology, and precision fermentation for renewable specialty ingredients. Company updates center on proprietary fermentation technology, the Barra Bonita precision fermentation plant in Brazil, ingredient commercialization, and partner arrangements for products such as fermented Reb M and sustainable squalene.
Recurring Amyris news also covers operating and financial results, cost and capital-structure initiatives, governance changes, and restructuring activity tied to its business transformation. The company's announcements describe how its technology platform, manufacturing assets, and licensing or supply relationships support specialty-ingredient production for consumer, food, pharmaceutical, and related markets.
Amyris (AMRS) and Ingredion (INGR) have agreed to dissolve their RealSweet joint venture, leading to a strategic restructuring of their business relationship. Under the new agreement, Amyris will take full ownership of the Precision Fermentation Plant located in Barra Bonita, Brazil. Meanwhile, Ingredion gains exclusive rights to utilize Amyris' technology for the manufacture and commercialization of fermented Reb M, a sweetener product. This restructuring aims to establish a foundation for commercial success and future collaboration between both companies.
Amyris (AMRS) has acquired Ingredion's 31% stake in the RealSweet Joint Venture, taking full ownership of their industrial precision fermentation plant in Barra Bonita, Brazil. As part of the agreement, Ingredion will receive exclusive access to Amyris' technology for manufacturing and commercializing fermented Reb M, while Amyris will earn royalties on Ingredion's future Reb M sales.
Additionally, Amyris is investing in the completion of a fourth independent precision fermentation line at the Barra Bonita plant, scheduled to be operational in early 2026. This expansion aligns with the company's 2030 strategic plan and aims to increase production capacity and flexibility for specialty ingredients manufacturing.
parameter name=\"positive\"[\"Full ownership of the Barra Bonita fermentation plant gives Amyris complete control over manufacturing operations\", \"New revenue stream through royalties from Ingredion's future Reb M sales\", \"Expansion with fourth fermentation line will increase production capacity and flexibility\", \"Strategic alignment with company's 2030 growth plan\"]Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Amyris, Inc. (Nasdaq: AMRS) announced an estimated $56 million in total revenue for Q1 2023, surpassing prior guidance of $50 million. The company is focusing on cost efficiency and liquidity to self-fund its initiatives, with a strategic review underway as part of its 'Fit-to-Win' program. The insourcing production at the technologically advanced Barra Bonita facility has progressed, with the plant now meeting product delivery targets. CEO John Melo expressed confidence in the company's operational efficiency and revenue growth strategy. Amyris expects to secure $335 million in earnouts and milestone payments and aims for an additional $200 million from transactions this year. A detailed update will be provided during the Q1 earnings call on May 9, 2023.
Amyris, Inc. (Nasdaq: AMRS) has completed a strategic transaction with Givaudan SA, securing exclusive worldwide licensing for key cosmetic ingredients including Neossance® Squalane and CleanScreen™. The deal is valued at approximately $500 million, comprising $200 million in upfront cash and up to $150 million in performance-based earnouts. This partnership enhances both companies' positions in sustainable beauty, leveraging Amyris' Lab-to-Market™ technology to produce high-performing bio-fermented ingredients. The collaboration follows a successful history in the commercialization of Bisabolol, further solidifying Amyris' market role in clean, sustainable consumer products.